Fig. 2. Evaluation of cisplatin cytotoxicity to NSCLC cells. A549, H1299, and SPC-A-1 cells were incubated with 0, 2.5, 5, 7.5, 10, and 12.5 μM of cisplatin for 48 h. A549/CDDP cells were incubated with 0, 2, 4, 8, 16, 32, and 64 μM of cisplatin for 48 h. The cell viability was detected by MTT assay. (A) The viability of A549 cells. *p < 0.05 vs. A549 cells without cisplatin treatment, n = 3. (B) The viability of H1299 cells. *p < 0.05 vs. H1299 cells without cisplatin treatment, n = 3. (C) The viability of SPC-A-1 cells. *p < 0.05 vs. SPC-A-1 cells without cisplatin treatment, n = 3. (D) The viability of A549/CDDP cells. *p < 0.05 vs. A549/CDDP cells without cisplatin treatment, n = 3.